This bill, titled the “cannabis supply chain integrity and anti-inversion act,” amends New York’s Cannabis Law to prohibit “cannabis inversion,” a term the bill defines as conduct involving illicit cannabis. It expands the definition of illicit cannabis to include cannabis on which required taxes have not been paid, cannabis sourced from unlicensed or unauthorized persons, and cannabis imported into New York State. The bill also targets false or unreliable certificates of analysis, missing or falsified inventory and chain-of-custody records, and the sale or transfer of illicit cannabis within the regulated market.
The bill creates a new enforcement framework for the Office of Cannabis Management and the Cannabis Control Board. It authorizes civil penalties, discipline, seizure, forfeiture, and destruction of illicit cannabis, and allows the office to seek temporary suspension pending investigation when there are reasonable grounds to believe a licensee, permittee, registrant, or laboratory is engaged in cannabis inversion. It also adds related grounds for revocation and emergency action, including fraudulent lab testing activity and violations involving cannabis inversion. The bill further limits suspension pending investigation to 30 days and bars repeated suspensions based on the same facts.
In practical terms, the bill would strengthen state oversight of the legal cannabis supply chain and impose new compliance obligations on licensees, permittees, registrants, and laboratory testing facilities. It would affect recordkeeping, testing, inventory tracking, and chain-of-custody requirements, while giving regulators more explicit authority to act against products or businesses suspected of moving illicit cannabis into the regulated market. It also updates the cease-and-desist authority in the Cannabis Law to expressly cover cannabis inversion.
The general sentiment reflected by the bill itself is strongly supportive of tighter market integrity and consumer protection. The findings section emphasizes that inversion threatens public health, undermines confidence in the regulated market, deprives the state of tax revenue, and harms compliant businesses. The bill passed the Senate, suggesting legislative support for the enforcement approach.
The main points of contention likely center on enforcement breadth and due process. The bill places the burden on licensees to rebut a presumption that cannabis is illicit when electronic inventory records are missing or inadequate, and it authorizes significant penalties and emergency suspensions. At the same time, it includes procedural limits, such as notice and hearing rights, a 30-day cap on suspension pending investigation, and a prohibition on successive suspensions based on the same facts, which appear designed to address concerns from regulated businesses and laboratories about overreach.
The bill would amend multiple sections of the Cannabis Law to create a new offense-like regulatory concept of cannabis inversion, broaden the definition of illicit cannabis, and expand the enforcement powers of the Office of Cannabis Management and the Cannabis Control Board. It would expose regulated actors to civil penalties, discipline, seizure and forfeiture of product, emergency suspension pending investigation, and revocation presumptions tied to illicit cannabis and fraudulent laboratory certificates of analysis. It also adds explicit authority to order cessation of cannabis inversion and indirect retail sales, affecting licensees, permittees, registrants, and laboratory testing facilities across the cannabis supply chain.
Overall sentiment appears favorable toward stronger cannabis regulation and market integrity. The bill’s findings frame the issue as a serious threat to consumer health, tax revenue, and lawful operators, and the measure advanced through the Legislature, including passage in the Senate. The structure of the bill suggests broad support for enforcement tools, while also reflecting an effort to preserve procedural safeguards for regulated parties.
The most notable tension is between aggressive anti-illicit-market enforcement and regulated businesses’ due process concerns. Critics of the approach may object to the presumption that cannabis is illicit when records are missing, the burden placed on licensees to prove lawful custody, and the size of the civil penalties. Supporters are likely to emphasize the need to stop diversion, counterfeit testing, and tax evasion. The bill responds to some of these concerns by limiting suspension pending investigation to 30 days, requiring written findings and documentation, and preserving hearing and appeal rights.